Please assess the completion status of the following clinical trial:

Trial Title: Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, healthy postmenopausal women with~  * Natural menopause and more than 5 years after their last menstrual period~ * or surgical menopause and more than 5 years after surgery~ * osteopenia (lumbar spine T score between 1 and 2.5 SD below the mean value in normal young women).~* With at least one risk factor for osteoporosis~Exclusion Criteria:~* Women who have received hormone replacement therapy (with estrogen and/or progestogen and/or androgen) or raloxifene within 3 months before visit 2 or calcitonin or calcitriol within 4 weeks before visit 2

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).